Tag:
Emergent BioSolutions
Latest Headlines
Latest Headlines
Emergent, VaxInnate sign pandemic flu vaccine deal
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
TB vaccine tested in infants of HIV-positive mothers
University of Cape Town's South African Tuberculosis Vaccine Initiative and Stellenbosch's Desmond Tutu TB Centre are recruiting infants to test a new tuberculosis vaccine for newborns of HIV-positive moms, a demographic not served by the current vaccine.
Targacept taps Stephen A. Hill to serve as president and CEO
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Novartis, Emergent headline $400M HHS plan to combat health threats
Several biopharma players--including Emergent Biosolutions, GlaxoSmithKline and Novartis--landed on the winning end of contracts from the U.S. Department of Health and Human Services to develop and churn out treatments against bioterror and pandemic threats. To fund the first phase of the effort, the HHS has committed $400 million.
Abbott nixes cancer drug alliance with Emergent BioSolutions
Emergent BioSolutions ( $EBS ) has suffered a setback in its campaign to expand into cancer drug development. Abbott Labs ( $ABT ) has decided to dump a partnership with Emergent on the development of
Emergent BioSolutions gets gov't order for BioThrax
Emergent BioSolutions could earn up to $1.25 billion over the next 5 years for providing 44.8 million doses of its BioThrax anthrax vaccine to the U.S. government. The developer revealed in May the
Aeras kicks off TB trial in HIV patients
In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study
U.S. increases Emergent BioSolutions' anthrax vax contract
Emergent BioSolutions is adding another 3.42 million doses to its 14.5 million-dose BioThrax contract with the U.S. government. The contract extension is worth an approximate $101 million; the
NIAID awards $46.3 million in vax grants and contracts
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two grants to vaccine makers for anthrax and hepatitis B vaccines, respectively. Emergent BioSolutions received a
Emergent buys Trubion for up to $135M
Emergent BioSolutions is buying Trubion Pharmaceuticals for $96.8 million up front and up to $38.7 million of success-based milestones. Emergent gains Trubion's two clinical-stage product candidates
